Augmentation of NAD+ by NQO1 attenuates cisplatin-mediated hearing impairment

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Kim, H J ^a   Oh, G S ^a   Shen, A ^a,b   Lee, S B ^a,b   Choe, S K ^a   Kwon, K B ^a,b   Lee, S ^c   Seo, K S ^c   Kwak, T H ^c   Park, R ^a,b   So, H S ^a,b  

^a Wonkwang University School of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

^c Sunkyong Industries   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; CISPLATIN; MICRORNA 34A; NAD(P)H QUINONE OXIDOREDUCTASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICRORNA; MIRN34 MICRORNA, MOUSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NQO1 PROTEIN, MOUSE; PARP1 PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEARING IMPAIRMENT; MOUSE; NONHUMAN; OTOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; HEARING LOSS; MALE; MICE; MICE, KNOCKOUT; MICRORNAS; NAD; NAD(P)H DEHYDROGENASE (QUINONE); POLY(ADP-RIBOSE) POLYMERASES; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903793099     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.255     Document Type: Article

References (60)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
2. Rybak LP, Somani S. Ototoxicity. Amelioration by protective agents. Ann N Y Acad Sci 1999; 884: 143-151.
3. Deavall DG, Martin EA, Horner JM, Roberts R. Drug-induced oxidative stress and toxicity. J Toxicol 2012; 2012: 645460.
4. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
5. Kim HJ, Lee JH, Kim SJ, Oh GS, Moon HD, Kwon KB et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010; 30: 3933-3946.
6. Jiang M, Yi X, Hsu S, Wang CY, Dong Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 2004; 287: F1140-F1147.
7. So H, Kim H, Lee JH, Park C, Kim Y, Kim E et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol 2007; 8: 338-355.
8. Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 2011; 301: F427-F435.
9. Oh GS, Kim HJ, Choi JH, Shen A, Choe SK, Karna A et al. Pharmacological activation of NQO1 increases NAD levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 2014; 85: 547-560.
10. Oka S, Hsu CP, Sadoshima J. Regulation of cell survival and death by pyridine nucleotides. Circ Res 2012; 111: 611-627.
11. Abdellatif M. Sirtuins and pyridine nucleotides. Circ Res 2012; 111: 642-656.
12. Imai S, Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci (Landmark Ed) 2009; 14: 2983-2995.
13. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci 2007; 32: 12-19.
14. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008; 14: 661-673.
15. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-3179.
16. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
17. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563.
18. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-159.
19. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
20. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005; 280: 43121-43130.
21. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
22. Mukhopadhyay P, Horvath B, Kechrid M, Tanchian G, Rajesh M, Naura AS et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011; 51: 1774-1788.
23. Shino Y, Itoh Y, Kubota T, Yano T, Sendo T, Oishi R. Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic Biol Med 2003; 35: 966-977.
24. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000; 129: 77-97.
25. Gaikwad A, Long DJ II, Stringer JL, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem 2001; 276: 22559-22564.
26. Pazdro R, Burgess JR. The antioxidant 3H-1,2-dithiole-3-thione potentiates advanced glycation end-product-induced oxidative stress in SH-SY5Y cells. Exp Diabetes Res 2012; 2012: 137607.
27. Jones CI III, Zhu H, Martin SF, Han Z, Li Y, Alevriadou BR. Regulation of antioxidants and phase 2 enzymes by shear-induced reactive oxygen species in endothelial cells. Ann Biomed Eng 2007; 35: 683-693.
28. Moscovitz O, Tsvetkov P, Hazan N, Michaelevski I, Keisar H, Ben-Nissan G et al. A mutually inhibitory feedback loop between the 20S proteasome and its regulator. NQO1. Mol Cell 2012; 47: 76-86.
29. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6: e17963.
30. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012; 72: 3038-3047.
31. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227-242.
32. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011; 17: 275-285.
33. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR et al. Betalapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995; 55: 3706-3711.
34. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, Park JH et al. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 2009; 58: 965-974.
35. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ et al. Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res 2009; 104: 842-850.
36. Kim YH, Hwang JH, Noh JR, Gang GT, Kim do H, Son HY et al. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res 2011; 91: 519-527.
37. Kim YH, Hwang JH, Noh JR, Gang GT, Tadi S, Yim YH et al. Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase. Free. Radic Biol Med 2012; 52: 880-888.
38. Lee JS, Park AH, Lee SH, Lee SH, Kim JH, Yang SJ et al. Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One 2012; 7: e47122.
39. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed) 2009; 14: 1116-1128.
40. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-199.
41. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-13426.
42. de Jongh FE, van Veen RN, Veltman SJ, deWit R, van der Burg ME, van den Bent MJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-1206.
43. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-1362.
44. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596.
45. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24.
46. Goodwin PM, Lewis PJ, Davies MI, Skidmore CJ, Shall S. The effect of gamma radiation and neocarzinostatin on NAD and ATP levels in mouse leukaemia cells. Biochim Biophys Acta 1978; 543: 576-582.
47. Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S et al. The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea. Eur J Biochem 1979; 101: 135-142.
48. Canto C, Auwerx J. NAD+ as a signaling molecule modulating metabolism. Cold Spring Harb Symp Quant Biol 2012; 76: 291-298.
49. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H et al. Kidneyspecific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem 2010; 285: 13045-13056.
50. Revollo JR, Li X. The ways and means that fine tune Sirt1 activity. Trends Biochem Sci 2013; 38: 160-167.
51. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20: 1754-1764.
52. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
53. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-626.
54. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
55. Brooks CL, GuW. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011; 2: 456-462.
56. Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J 2007; 21: 2642-2654.
57. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29: 1363-1374.
58. Chen LF, Greene WC. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) 2003; 81: 549-557.
59. Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Park SK et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun 2012; 419: 206-210.
60. Gang GT, Kim YH, Noh JR, Kim KS, Jung JY, Shong M et al. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity. Toxicol Lett 2013; 221: 165-175.